199 related articles for article (PubMed ID: 6229416)
1. Characterization and antithrombotic action of tissue plasminogen activator.
Bergqvist D; Nilsson IM; Pandolfi M
Experientia; 1984 Jan; 40(1):67-8. PubMed ID: 6229416
[TBL] [Abstract][Full Text] [Related]
2. Effects of pro-urokinase and urokinase on the fibrinolytic system in man.
Trübestein G; Popov S; Wolf H; Welzel D
Haemostasis; 1987; 17(4):238-44. PubMed ID: 2442078
[TBL] [Abstract][Full Text] [Related]
3. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
Veremeenko KN; Kizim AI
Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
5. [Molecular mechanisms of thrombolytic therapy].
Lijnen HR; Collen D
Haemostasis; 1986; 16 Suppl 4():3-15. PubMed ID: 2945768
[No Abstract] [Full Text] [Related]
6. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
Thorsen S; Müllertz S; Suenson E; Kok P
Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
[TBL] [Abstract][Full Text] [Related]
7. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis.
Lee KN; Jackson KW; McKee PA
Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133
[TBL] [Abstract][Full Text] [Related]
8. The fibrinolytic system in man.
Collen D; Lijnen HR
Crit Rev Oncol Hematol; 1986; 4(3):249-301. PubMed ID: 2420482
[TBL] [Abstract][Full Text] [Related]
9. Thrombolytic therapy in the eighties.
Verstraete M; Collen D
Blood; 1986 Jun; 67(6):1529-41. PubMed ID: 2423156
[No Abstract] [Full Text] [Related]
10. Interaction of plasminogen activators and inhibitors with plasminogen and fibrin.
Lijnen HR; Collen D
Semin Thromb Hemost; 1982 Jan; 8(1):2-10. PubMed ID: 6460318
[No Abstract] [Full Text] [Related]
11. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Collen D; Lijnen HR
Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
[TBL] [Abstract][Full Text] [Related]
12. [The role of histidine-rich glycoprotein in the regulation mechanism of fibrinolysis in humans].
Lijnen HR
Verh K Acad Geneeskd Belg; 1982; 44(5-6):307-29. PubMed ID: 6223461
[No Abstract] [Full Text] [Related]
13. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E
Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856
[No Abstract] [Full Text] [Related]
14. Human urokinase and porcine tissue plasminogen activator. A comparative study of the mechanism of fibrinolysis, and the effect of natural proteinase inhibitors and omega-aminocarboxylic acids.
Thorsen S
Dan Med Bull; 1977 Oct; 24(5):189-206. PubMed ID: 908205
[No Abstract] [Full Text] [Related]
15. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture.
Collen D
Thromb Haemost; 1980 Jun; 43(2):77-89. PubMed ID: 6450468
[No Abstract] [Full Text] [Related]
16. Concepts of clot lysis.
Francis CW; Marder VJ
Annu Rev Med; 1986; 37():187-204. PubMed ID: 2939790
[TBL] [Abstract][Full Text] [Related]
17. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
Bode C; Eberle T; Runge M; Haber E; Kübler W
Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723
[No Abstract] [Full Text] [Related]
18. Intracellular activation of the fibrinolytic cascade in the Quebec Platelet Disorder.
Sheth PM; Kahr WH; Haq MA; Veljkovic DK; Rivard GE; Hayward CP
Thromb Haemost; 2003 Aug; 90(2):293-8. PubMed ID: 12888877
[TBL] [Abstract][Full Text] [Related]
19. Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system.
Mattsson C; Nyberg-Arrhenius V; Wallén P
Thromb Res; 1981 Mar; 21(6):535-45. PubMed ID: 7022741
[No Abstract] [Full Text] [Related]
20. Differences in the reactivities of human urokinase and the porcine tissue plasminogen activator.
Thorsen S; Astrup T
Haemostasis; 1976; 5(5):295-305. PubMed ID: 14058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
